List view / Grid view

Chronic lymphocytic leukaemia (CLL)

AACR: BTK degrader could treat CNS B-cell malignancies

10 April 2024 | By Catherine Eckford (European Pharmaceutical Review)

New data suggests the small molecule therapeutic could also benefit autoimmune disorders with involvement in the central nervous system, such as multiple sclerosis.

news

Long-term findings from CAR NK cell therapy trial revealed

18 January 2024 | By Catherine Eckford (European Pharmaceutical Review)

One-year results from a cancer therapy trial has reported key findings for the selection criteria for allogeneic cord blood donors in CAR NK cell manufacturing.

news

NICE recommends therapy duo for advanced leukaemia

21 April 2023 | By Catherine Eckford (European Pharmaceutical Review)

Janssen states Imbruvica® plus venetoclax will provide "a much-needed new treatment option" for chronic lymphocytic leukaemia.

news

AstraZeneca BTK inhibitor tablet approved in EU for leukaemia

22 February 2023 | By Catherine Eckford (European Pharmaceutical Review)

The tablet formulation for AstraZeneca’s BTK inhibitor has gained EU approval for co-administration with gastric acid-reducing agents in chronic lymphocytic leukaemia patients.

news

MHRA authorises BRUKINSA^® in Great Britain for two cancers

20 January 2023 | By Catherine Eckford (European Pharmaceutical Review)

BRUKINSA® (zanubrutinib) has been authorised by the MHRA for chronic lymphocytic leukaemia and marginal zone lymphoma in Great Britain.

3d illustration of T cells attacking cancer cells - idea of T-cell therapy

article

Advancing cell therapies – γδ T cells and the combination factor

13 July 2022 | By Hannah Balfour (European Pharmaceutical Review)

In this Q&A, Bryan Kobel, Chief Executive Officer of TC Biopharm, discusses innovations in cell therapies, introducing the company’s work in gamma delta (γδ) T-cell technologies and his predictions for the future of cell therapy development.

news

Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, Oct 2021

1 November 2021 | By Anna Begley (European Pharmaceutical Review)

EMA's drug safety committee (PRAC) assessed risks with COVID-19 vaccines and identified no risk of death with Imbruvica and ACE inhibitors.

Man in white coat (oncologist) holding hand of female cancer patient in a hospital bed

news

Chemotherapy-free combination shows potential in lymphocytic leukaemia trial

8 June 2021 | By Hannah Balfour (European Pharmaceutical Review)

Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.

Blood smear under microscopy showing chronic lymphoblastic leukemia (CLL)

news

Imbruvica^®-based regimens induce lasting remissions in leukaemia trials

20 May 2021 | By Hannah Balfour (European Pharmaceutical Review)

Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.

sign of the European Medicines Agency building in Amsterdam [Credit: martinbertrand.fr/Shutterstock.com].

news

European Medicines Agency’s CHMP meeting highlights March 2021

29 March 2021 | By Hannah Balfour (European Pharmaceutical Review)

In its March meeting the EMA’s human medicines committee recommended five medicines for approval and concluded its review of regdanvimab as a treatment for COVID-19.

news

New oral chronic lymphocytic leukaemia treatment made available on NHS

19 March 2021 | By Hannah Balfour (European Pharmaceutical Review)

AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.

news

NICE recommends new chemo-free chronic lymphocytic leukaemia treatment

13 November 2020 | By Hannah Balfour (European Pharmaceutical Review)

More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.

news

FDA approves IMBRUVICA^® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma

22 April 2020 | By Victoria Rees (European Pharmaceutical Review)

IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.

news

EC approves KTE-X19 for treatment of mantle cell lymphoma

30 January 2020 | By Joe Doherty (European Pharmaceutical Review)

KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.

news

Imbruvica^® granted expanded use from European Commission

14 August 2019 | By Victoria Rees (European Pharmaceutical Review)

The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Chronic lymphocytic leukaemia (CLL)